news
Drugs in development for cancer may also fight brain diseases
PARP inhibitors show promise in preventing toxic accumulations of brain disease proteins in Penn research study...
List view / Grid view
Hit-to-Lead
article
The evolving role of three dimensional in-vitro cell culture techniques in drug discovery
Drug discovery is a lengthy process that proceeds through several stages. High throughput screening (HTS) utilising whole-cell based screening assays play a fundamental role as a starting point for identifying novel compounds in the drug discovery process.1,2
article
Streamlining drug discovery assays for cancer and cardiovascular disease
For lead optimisation, target-based assays are still the most affordable means of rapidly performing fast iterations and remain core to screening. However, the desire for biological relevance is driving ongoing growth in cell-based assays.
article
Automated assessment of liver and cardiac toxicities in lead optimisation
This webinar, supported by Tecan, focused on the automated assessment of liver and cardiac toxicities in lead optimisation, using biochemical and human iPS cell assays.
webinar
Automated assessment of Liver and Cardiac toxicities in lead optimisation, using biochemical and human iPS cell assays
27 April 2018 | By TECAN
ABOUT THIS WEBINAR: In this two-part webinar, both automation of P450 (CYP) assays and the automatisation of cellular differentiation processes and compound testing using human induced pluripotent stem cells based assays was covered. Metabolism of drugs is a key factor in compound toxicity, and automated assays which monitor inhibition or…
article
Streamlining drug discovery assays for cancer and cardiovascular disease
Declining R&D productivity is a key challenge in the pharmaceutical industry. To increase the success rate of candidate drugs entering the clinical phase, companies must address the early stages of drug discovery.
article
Drug Target Review – Issue #1 2018
In this issue: how customised cell engineering advances immunotherapy, how insights into auto-immunity are providing new opportunities for immune-oncology, and advances in lab automation and robotics are accelerating the pace of antimicrobial therapy.
webinar
Streamlining drug discovery assays for cancer and cardiovascular disease
1 February 2018 | By PerkinElmer
This webinar discussed a screening assay that recapitulates the activation of ER stress sensor IRE1 and an assay to quantify cell migration phenotypes, as applied to cardiovascular target validation and drug discovery.
article
Identification of hits and leads for human African trypanosomiasis
Neglected tropical diseases (NTD) affect more than one billion people and new targets and drugs are needed to tackle these infections. The multi-disciplinary NMTrypI consortium has identified a number of different compound classes which could be effective against these diseases. This article reviews some of these compounds...
article
Expert view: Optimising the hit-to-lead workflow
Hits identified in high-throughput screens are evaluated within the hit-to-lead phase of drug discovery, where they undergo an iterative optimisation process employing a variety of techniques to identify promising lead compounds to move forward to the lead optimisation phase.
article
Expert view: Improving hit-to-lead results
Declining R&D productivity is a key challenge in the pharmaceutical industry today.
article
Hit To Lead In-Depth Focus 2017
In this In-Depth Focus we look at a pragmatic approach to hit validation following biochemical high-throughput screening as well as identification of hits and leads for human African trypanosomiasis.
article
Drug Target Review – Issue #4 2017
Issue 4 of Drug Target Review looks at artificial intelligence in drug discovery and features In-Depth Focuses on Screening, Hit to Lead and Informatics.
news
Exclusive speaker interview with Professor Nagy Habib – MiNA Therapeutics/Imperial College London
SMi are delighted to have, Nagy Habib, Head of HPB Surgery, Imperial College London and Co-Founder, MiNA Therapeutics, as the Keynote Address for day 1 at RNA Therapeutics 2018!
news
Feinstein Institute identifies potential cause for lupus
A protein has been identified as a possible cause for the adverse reaction of the immune system in patients suffering from lupus.
